Ready For Record-Busting Move? IntelliPharmaCeutics International Inc. (IPCI), CorMedix, Inc. (CRMD)

A look at IPCI technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 59.81 point. Its trading volume has added 1152658 shares compared to readings over the past three months as it recently exchanged 2512658 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 1360000 shares, and this is 1.85 times the normal volume.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) dipped by -31.09% over the past three months which led to its overall six-month decrease to stand at -89.11%. The equity price rose 1.42% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a 24.07% gain over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -95.07% and is now up by 50.89% since start of this year.

Experts from research firms are bullish about the near-term performance of IntelliPharmaCeutics International Inc. (IPCI) with most of them predicting a $27.5 price target on a short-term (12 months) basis. The average price target by the analysts will see a 7332.43% rise in the stock and would lead to IPCI’s market cap to surge to $441.38M. The stock has been rated an average 2, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 1 analysts that track IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) and find out that 1 of them rated it as a Hold. 0 of the 0 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

The price of CorMedix, Inc. (NYSE:CRMD) currently stands at $2.13 after it went up by $0.16 or 8.12% and has found a strong support at $2.01 a share. If the CRMD price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $1.9 mark would also be bad for the stock as it means that the stock would plunge by 10.8% from its current position. However, if the stock price is able to trade above the resistance point around $2.21, then it could likely surge higher to try and break the upward resistance which stands at $2.3 a share. Its average daily volatility over the past one month stands at 10.63%. The stock has plunged by 7.04% from its 52-weeks high of $1.98 which it reached on Oct. 15, 2018. In general, it is 92.02% above its 52-weeks lowest point which stands at $0.17 and this setback was observed on May. 22, 2018.

Analysts have predicted a price target for CorMedix, Inc. (CRMD) for 1 year and it stands at an average $4.75/share. This means that it would likely increase by 123% from its current position. The current price of the stock has been moving between $1.98 and $2.18. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $3.5. On the other hand, one analyst is super bullish about the price, setting a target as high as $6.

The CRMD stock Stochastic Oscillator (%D) is at 69.01%, which means that it is currently neutral. The shares P/S ratio stands at 432.69 which compares to the 7.55 recorded by the industry or the 9.88 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone down, with a quarterly decrease rate of -15.1% over the past five years.

Analysts view CorMedix, Inc. (NYSE:CRMD) as a Buy, with 2 consensus rating. Reuters surveyed 2 analysts that follow CRMD and found that 1 of those analysts rated the stock as a Hold. The remaining 1 were divided, with 1 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying CorMedix, Inc. (CRMD) shares or sell it if they already own it.